TD Waterhouse technical resource has an intermediate buy on TLT with an expected range of 0.33 - 0.35
Yea not that great but you have to start so,e where. Once the PP is directly out of the way we will still be dealing with profit taking and those that bought the PP and will be liquidating a piece to reduce their risk.
Nevertheless we know there is a lot of potentially positive news coming in Q4 so the intermediate buy range is but a short term step in the move to fill the price gap above the market and eventually to move to multi year highs around 0.75
My projection is over $1 by Q1 2023 assuming good news. The vaccine trial is where I see the greatest upside leverage in the short run - keep in mind that the analysts have assigned no value to it in their valuation model.
The lack of information from the company is not helping. Their last corporate update was in June. They have not articulated a vision of how they would capitalize if and when they get BTD & AA on the bladder side and a positive Covid animal trial on the vaccine side.
Scanning the company website is not helpful. They stop posting newsletters. Their Corporate Factsheet is years old. They stated that once a majority of clincs for the phase 2 trial were setup they would begin Phase 1 trials for lung/brain cancer. As far as I can tell they have never gotten to the expected number of trial locations. It would be helpful to understand why and whether they are now doing procedures in each location.
As I have said before I have more questions than answers, do you? At some point in time the company will need to start answering those questions, fill in the blanks so to speak, if they want to grow the share price. Continuing to fish in this shareholder pond for equity is not doing it and the company is going to continue to need money for development and commercialization.